EHA 2019 | Primary endpoint results of the CLL12 trial
Barbara Eichhorst
• 15 Jun 2019
The primary endpoint results of the CLL12 trial (NCT02863718) were presented at the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. We discussed the trial, which investigated ibrutinib vs. a placebo in asymptomatic, untreated chronic lymphocytic leukemia (CLL) patients, with Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, here at the meeting.
